A novel immunoglobulin, designated 2H7, demonstrates remarkable cross-reactivity against dual CD20 antigens found in both and human species. Its discovery holds potential for preclinical studies into disease therapies, https://www.targetmol.com/compound/anti-monkey-human-cd20-antibody-2h7